The Abdul Latif Jameel Clinic (Jameel Clinic) for Machine Learning in Health at the Massachusetts Institute of Technology (MIT) reached an agreement for an inaugural collaboration with Janssen R&D, LLC. This agreement allows MIT’s Artificial Intelligence and Healthcare arm at the Jameel Clinic and the Data Science team at Janssen R&D to discuss the development and application of artificial intelligence (AI) and machine learning capabilities to advance drug discovery and development. Specifically, this would span the diagnosis of disease, development of treatments, prediction of treatment response, development of novel biomarkers, clinical trial optimization, medical imaging, among other projects. Centered within the Abdul Latif Jameel Clinic for Machine Learning in Health, the agreement leverages the combined expertise of both organizations.
The new program spans interdisciplinary faculty, students, researchers, and staff within the Jameel Clinic from across the Institute as well as the Data Science team at Janssen R&D who are working at the intersection of AI and human health, ensuring that they can devote their energies to expanding the limits of knowledge, imagination, and impact. This program coalesces disparate disciplines, merges theory and practical implementation, combines algorithm and hardware innovations, and creates multidimensional collaborations between academia and industry.